Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Endometrial Cancer
API-59CJ-OMe may possess therapeutic potential for some endometrial cancers
January 20th, 2005
Findings from researchers at Ohio State University suggest that API-59CJ-OMe may possess therapeutic potential for some endometrial cancers. "The PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor is mutated in 40-50% of human endometrial cancers. PTEN exerts its effects in part via inhibition of the antiapoptotic protein AKT. "We demonstrate that two endometrial cancer cell lines that harbor PTEN mutations, Ishikawa and RL95-2, have high levels of phosphorylated AKT and high AKT kinase activity," wrote J. Lin and coauthors. The researchers continued, "Two additional endometrial cancer cell lines that...
Source: Women's Health Weekly (2005-01-20)
|
